BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nanjing Sanhome Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nanjing Sanhome Pharmaceutical's 
 drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06080776-2226@assetmemo.bio
DTSTAMP:20261121T010639Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Rilertinib (SH-1028): Phase 3 readout est. (NCT06080776)
DESCRIPTION:Rilertinib (SH-1028)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage
  II-IIIB NSCLC With Sensitizing EGFR Mutations\nEstimated primary completi
 on: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rilertinib-sh-1028#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06080776
URL:https://assetmemo.bio/drug/rilertinib-sh-1028#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
